Mateoc, T.; Suciu, I.-M.; Gaiță, D.; Minodora, A.; Popescu, R.; Vlad, T.; Flangea, C.; Muntean, C.; Vlad, D.-C.
Early SGLT2 Inhibitor Therapy in Acute Coronary Syndrome: Mitigating Adverse Remodeling in High-Risk Phenotypes—A Real-World Study. Medicina 2026, 62, 205.
https://doi.org/10.3390/medicina62010205
AMA Style
Mateoc T, Suciu I-M, Gaiță D, Minodora A, Popescu R, Vlad T, Flangea C, Muntean C, Vlad D-C.
Early SGLT2 Inhibitor Therapy in Acute Coronary Syndrome: Mitigating Adverse Remodeling in High-Risk Phenotypes—A Real-World Study. Medicina. 2026; 62(1):205.
https://doi.org/10.3390/medicina62010205
Chicago/Turabian Style
Mateoc, Teodora, Ioana-Maria Suciu, Dan Gaiță, Andor Minodora, Roxana Popescu, Tania Vlad, Corina Flangea, Călin Muntean, and Daliborca-Cristina Vlad.
2026. "Early SGLT2 Inhibitor Therapy in Acute Coronary Syndrome: Mitigating Adverse Remodeling in High-Risk Phenotypes—A Real-World Study" Medicina 62, no. 1: 205.
https://doi.org/10.3390/medicina62010205
APA Style
Mateoc, T., Suciu, I.-M., Gaiță, D., Minodora, A., Popescu, R., Vlad, T., Flangea, C., Muntean, C., & Vlad, D.-C.
(2026). Early SGLT2 Inhibitor Therapy in Acute Coronary Syndrome: Mitigating Adverse Remodeling in High-Risk Phenotypes—A Real-World Study. Medicina, 62(1), 205.
https://doi.org/10.3390/medicina62010205
